New drug duo targets hard-to-treat cancers with rare genetic marker
NCT ID NCT07417501
First seen Feb 22, 2026 · Last updated May 23, 2026 · Updated 16 times
Summary
This study tests whether combining lenvatinib (a targeted therapy) with a PD-1 inhibitor (immunotherapy) can shrink or slow advanced solid tumors that have a specific genetic change called 11q13 amplification. About 60 adults with various cancers (like esophageal, head and neck, breast, lung, or liver) will receive the same treatment. Researchers will track tumor response and side effects to see if this approach is effective and safe.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SOLID TUMORS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Tongji Hospital
Wuhan, Hubei, China
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.